Floatz logo

Camustine

Glioblastoma

Leland MethenySmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

341 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 3BB
(+)-Vincristine
University of Cincinnati
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
Capecitabine
Northwell Health
Phase 2BB

View all 50 →

Same molecule, other indications

Camustine is also rated in:

Hodgkins lymphomaActive
BBB
Indicative · Phase 2
74 / 100
View asset →
B-cell non-Hodgkin lymphomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
central nervous system neoplasmDormant
BBB
Indicative · Phase 3
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →